Literature DB >> 11090287

Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils.

C Redondo1, A M Damas, A Olofsson, E Lundgren, M J Saraiva.   

Abstract

Familial Amyloidotic Polyneuropathy (FAP) is caused by the assembly of TTR into an insoluble beta-sheet. The TTR tetramer is thought to dissociate into monomeric intermediates and subsequently polymerise into the pathogenic amyloid form. The biochemical mechanism behind this transformation is unknown. We characterised intermediate TTR structures in the in vitro amyloidogenesis pathway by destabilising the AB loop through substitution of residue 78. Changes at this residue, should destabilise the TTR tetrameric fold, based on the known crystallographic structure of a Leu55Pro transthyretin variant. We generated a soluble tetrameric form of TTR that is recognised by a monoclonal antibody, previously reported to react only with highly amyloidogenic mutant proteins lacking the tetrameric native fold and with amyloid fibrils. BIAcore system analysis showed that Tyr78Phe had similar binding properties as synthetic fibrils. The affinity of this interaction was 10(7) M(-1). We suggest that the tetrameric structure of Tyr78Phe is altered due to the loosening of the AB loops of the tetramer, leading to a structure that might represent an early intermediate in the fibrillogenesis pathway. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090287     DOI: 10.1006/jmbi.2000.4220

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  13 in total

1.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.

Authors:  Luís Gales; Sandra Macedo-Ribeiro; Gemma Arsequell; Gregorio Valencia; Maria João Saraiva; Ana Margarida Damas
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

Review 3.  Surface plasmon resonance for the analysis of beta-amyloid interactions and fibril formation in Alzheimer's disease research.

Authors:  Marie-Isabel Aguilar; David H Small
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

4.  Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.

Authors:  Mobina Alemi; Sara C Silva; Isabel Santana; Isabel Cardoso
Journal:  CNS Neurosci Ther       Date:  2017-06-01       Impact factor: 5.243

Review 5.  Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.

Authors:  Giacomo Tini; Pier Filippo Vianello; Chiara Gemelli; Marina Grandis; Marco Canepa
Journal:  J Cardiovasc Transl Res       Date:  2019-01-02       Impact factor: 4.132

6.  Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.

Authors:  Maria Rosário Almeida; Bárbara Macedo; Isabel Cardoso; Isabel Alves; Gregorio Valencia; Gemma Arsequell; Antoni Planas; Maria João Saraiva
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

7.  Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation.

Authors:  Giulietta Riboldi; Roberto Del Bo; Michela Ranieri; Francesca Magri; Monica Sciacco; Maurizio Moggio; Nereo Bresolin; Stefania Corti; Giacomo P Comi
Journal:  Case Rep Neurol       Date:  2011-02-23

8.  Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD.

Authors:  Anabela C Teixeira; Maria J Saraiva
Journal:  J Cell Mol Med       Date:  2013-02-07       Impact factor: 5.310

Review 9.  Recent advances in transthyretin amyloidosis therapy.

Authors:  Mitsuharu Ueda; Yukio Ando
Journal:  Transl Neurodegener       Date:  2014-09-13       Impact factor: 8.014

10.  Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.

Authors:  Natalie J Galant; Antoinette Bugyei-Twum; Rishi Rakhit; Patrick Walsh; Simon Sharpe; Pharhad Eli Arslan; Per Westermark; Jeffrey N Higaki; Ronald Torres; José Tapia; Avijit Chakrabartty
Journal:  Sci Rep       Date:  2016-04-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.